Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.26, $0.05 worse than the analyst estimate of $2.31. Revenue for the quarter came in at $336 million versus the consensus estimate of $338.86 million.

"During the first quarter of 2016, we executed on our business model by delivering strong top- and bottom-line growth and commenced promotion of Defitelio in the U.S. immediately following FDA approval. Defitelio is the first and only approved treatment in the U.S. for patients who develop hepatic VOD with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation," said Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "For 2016, we will continue to invest in the organic growth of our key products, including new indications, and the advancement of our development pipeline. Diversification of our product portfolio through internal and corporate development efforts remains a high priority as we seek to identify and acquiredifferentiated and long-lived therapeutic options for patients."

GUIDANCE:

Jazz Pharmaceuticals sees FY2016 EPS of $11.00-$11.50, versus the consensus of $11.40. Jazz Pharmaceuticals sees FY2016 revenue of $1.49-1.55 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Mattel (MAT) Tops Q1 EPS by 7c, Revenue Misses, Offers Guidance
• Weatherford International plc (WFRD) Tops Q1 EPS by 6c